The FDA has approved a new type of painkiller that doesn't come with the risks of addiction and overdose associated with opioids.

The FDA recently approved Vertex Pharmaceuticals Incorporated’s Journavx (suzetrigine), a first-in-class non-opioid medication for treating moderate to severe acute pain in adults. Journavx, approved ...

The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...

Suzetrigine prevents pain signals from reaching the brain and doesn't give an opioid-like high, making it non-addictive—but ...

The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...

The FDA has approved Journavx 50 mg oral tablets for the treatment of moderate to severe acute pain in adults, according to a ...

The Food and Drug Administration has approved a first-of-its-kind non-opioid pain medication, providing a new option for adults experiencing moderate to severe acute pain.Journavx received FDA ...

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

For those who may need relief from pain, Journavx symbolizes not only a new option but also a significant step forward in how we can tackle the challenges of pain management in the 21st century. The ...

The drug, suzetrigine, made by Boston-based Vertex Pharmaceuticals and to be sold as Journavx, works only on nerves outside ...

Below, check out the roundup of California Healthline's coverage. For today's national health news, read KFF Health News' Morning Briefing.